Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

gamma-Secretase: characterization and implication for Alzheimer disease therapy.

Xu M, Lai MT, Huang Q, DiMuzio-Mower J, Castro JL, Harrison T, Nadin A, Neduvelil JG, Shearman MS, Shafer JA, Gardell SJ, Li YM.

Neurobiol Aging. 2002 Nov-Dec;23(6):1023-30.

PMID:
12470798
2.

Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1.

Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelil JG, Register RB, Sardana MK, Shearman MS, Smith AL, Shi XP, Yin KC, Shafer JA, Gardell SJ.

Nature. 2000 Jun 8;405(6787):689-94.

PMID:
10864326
3.

Gamma-secretase: a catalyst of Alzheimer disease and signal transduction.

Li YM.

Mol Interv. 2001 Oct;1(4):198-207. Review.

PMID:
14993342
4.

Presenilin-1 and presenilin-2 exhibit distinct yet overlapping gamma-secretase activities.

Lai MT, Chen E, Crouthamel MC, DiMuzio-Mower J, Xu M, Huang Q, Price E, Register RB, Shi XP, Donoviel DB, Bernstein A, Hazuda D, Gardell SJ, Li YM.

J Biol Chem. 2003 Jun 20;278(25):22475-81. Epub 2003 Apr 8.

5.

Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide.

Lammich S, Okochi M, Takeda M, Kaether C, Capell A, Zimmer AK, Edbauer D, Walter J, Steiner H, Haass C.

J Biol Chem. 2002 Nov 22;277(47):44754-9. Epub 2002 Sep 9.

6.

Relationship between presenilinase and gamma-secretase.

Xia W.

Drug News Perspect. 2003 Mar;16(2):69-74. Review.

PMID:
12792666
7.

Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors.

Weihofen A, Lemberg MK, Friedmann E, Rueeger H, Schmitz A, Paganetti P, Rovelli G, Martoglio B.

J Biol Chem. 2003 May 9;278(19):16528-33. Epub 2003 Mar 5.

8.

Secretase as a target for Alzheimer's disease.

Wolfe MS.

Curr Top Med Chem. 2002 Apr;2(4):371-83. Review.

PMID:
11966461
9.

Endoproteolysis of the ER stress transducer ATF6 in the presence of functionally inactive presenilins.

Steiner H, Winkler E, Shearman MS, Prywes R, Haass C.

Neurobiol Dis. 2001 Aug;8(4):717-22.

PMID:
11493036
10.

Identification of gamma-secretase inhibitor potency determinants on presenilin.

Zhao B, Yu M, Neitzel M, Marugg J, Jagodzinski J, Lee M, Hu K, Schenk D, Yednock T, Basi G.

J Biol Chem. 2008 Feb 1;283(5):2927-38. Epub 2007 Nov 21.

11.

The inhibition of gamma-secretase as a therapeutic approach to Alzheimer's disease.

Tomita T, Iwatsubo T.

Drug News Perspect. 2004 Jun;17(5):321-5. Review.

PMID:
15334182
12.

gamma-Secretase inhibitors as molecular probes of presenilin function.

Wolfe MS.

J Mol Neurosci. 2001 Oct;17(2):199-204. Review.

PMID:
11816793
13.
14.

Aspartyl protease inhibitor pepstatin binds to the presenilins of Alzheimer's disease.

Evin G, Sharples RA, Weidemann A, Reinhard FB, Carbone V, Culvenor JG, Holsinger RM, Sernee MF, Beyreuther K, Masters CL.

Biochemistry. 2001 Jul 27;40(28):8359-68.

PMID:
11444983
16.

Gamma-secretase--intramembrane protease with a complex.

Wolfe MS.

Sci Aging Knowledge Environ. 2003 Mar 19;2003(11):PE7.

PMID:
12844518
18.

Mechanism of gamma-secretase cleavage activation: is gamma-secretase regulated through autoinhibition involving the presenilin-1 exon 9 loop?

Knappenberger KS, Tian G, Ye X, Sobotka-Briner C, Ghanekar SV, Greenberg BD, Scott CW.

Biochemistry. 2004 May 25;43(20):6208-18.

PMID:
15147205
19.

BACE1: the beta-secretase enzyme in Alzheimer's disease.

Vassar R.

J Mol Neurosci. 2004;23(1-2):105-14. Review.

PMID:
15126696
20.

PEN-2 enhances gamma-cleavage after presenilin heterodimer formation.

Shiraishi H, Sai X, Wang HQ, Maeda Y, Kurono Y, Nishimura M, Yanagisawa K, Komano H.

J Neurochem. 2004 Sep;90(6):1402-13.

Supplemental Content

Support Center